共 48 条
[1]
Figlin R(2012)Novel agents and approaches for advanced renal cell carcinoma J Urol 188 707-715
[2]
Sternberg C(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124
[3]
Wood CG(2013)Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 722-731
[4]
Motzer RJ(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-134
[5]
Hutson TE(2015)Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma Eur Urol 67 952-958
[6]
Tomczak P(2013)Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC) Br J Cancer 109 2998-3004
[7]
Motzer RJ(2016)Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan Target Oncol 11 175-182
[8]
Hutson TE(2010)EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 398-406
[9]
Cella D(2015)EAU guidelines on renal cell carcinoma: 2014 update Eur Urol 67 913-924
[10]
Escudier B(2014)Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma–comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off Jpn J Clin Oncol 44 270-277